Norwich City columnist Will Jennings recalls a glorious night at Watford when Josh Sargent was the undisputed star of the show ...

An icon of a desk calendar. An icon of a circle with a diagonal line across. An icon of a block arrow pointing to the right. An icon of a paper envelope. An icon of the Facebook "f" mark. An icon ...

I had to take a look at Catapult Sports because of its exploding share price. As an elite amateur athlete*, it’s an analysis that combines my love of high-performance sports with my passion for ...

Ah, the scorpion lollipop, a symbol of the Sonoran Desert. I like them, if only for the campiness of the dark, goth-looking scorpion encased unhappily in a gentle green, pink or blue. That said, ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

For a detailed explanation of Carl's technical analysis methodology, be sure to check out this ChartWatch Primer. Carl has over 30-year's investing experience, helping investors navigate several bull ...

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus." Under the terms of ...

Eli Lilly has turned to a biotechnology startup for help building its pipeline of cancer drugs, agreeing on Monday to purchase an experimental cancer drug from privately held Scorpion Therapeutics for ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...